MicroRNA-335 Acts as a Candidate Tumor Suppressor in Prostate Cancer

Xiong, Shangkun; Lin, Tianxin; Xu, Kecheng; Dong, Wen; Ling, Xuemei; Jiang, Funeng; Guo, Cheng; Zhong, Weide; Huang, Jian

doi:10.1007/s12253-013-9613-5

Cited by 36 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on bioinformatical predication, a luciferase reporter assay was performed and PAX6 was identified as a novel target of miR-335, which has been demonstrated to be implicated in various types of cancer (14)(15)(16)(17)(18)(19)(20)(21)(22). However, the detailed role of miR-335 in the development and progression of various types of cancer remains controversial.…”

Section: Discussionmentioning

confidence: 99%

“…miR-335 has been demonstrated to be implicated in multiple types of malignant tumor, including small cell lung cancer, osteosarcoma, ovarian cancer, prostate cancer, hepatocellular carcinoma, meningioma and gastric cancer (14)(15)(16)(17)(18)(19)(20)(21)(22). Recently, Jiang et al have suggested that miR-335 upregulation is associated with advanced tumor progression in glioma and is an independent marker for the predication of the clinical outcome of patients with glioma (23).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells

Cheng

Cao²,

Chen

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Paired box 6 (PAX6), a highly conserved transcription factor, is important in glioma. However, the molecular mechanisms involved remain unclear. The present study demonstrated that the expression of PAX6 was significantly reduced with the malignancy of glioma and also identified PAX6 as a novel target of microRNA (miR)-335, which was significantly upregulated in glioma. The inhibition of miR-335 increased the protein expression of PAX6, whereas the upregulation of miR-335 suppressed its expression in human glioma U251 and U87 cells. Furthermore, upregulation of miR-335 promoted U251 cell proliferation, colony formation and invasion, which was reversed by the overexpression of PAX6. Furthermore, the present study demonstrated that the effect of miR-335 on U251 cell invasion was via the modulation of matrix metalloproteinase (MMP)-2 and MMP-9 expression by targeting PAX6. In conclusion, the present study demonstrated that PAX6, as a novel target of miR-335, has an anti-oncogenic function in glioma, and thus PAX6 may serve as a therapeutic target for glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells

Cheng

Cao²,

Chen

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The upregulation of miR-335 may have inhibited gastric cancer cell invasion and metastasis in vitro and in vivo by directly targeting SP1, as well as acting indirectly through the Bcl-W-induced phosphoinositide 3-kinase-Akt-SP1 pathway (31). The reduced expression of miR-335 was also identified in human prostate cancer tissues and cell lines; miR-335 expression level was associated with a high Gleason Score, advanced clinical stage and metastasis in patients with prostate cancer (32). Enforced miR-335 expression decreased the growth and metastatic characteristics of prostate cancer cells in vitro (32).…”

Section: Discussionmentioning

confidence: 94%

“…The reduced expression of miR-335 was also identified in human prostate cancer tissues and cell lines; miR-335 expression level was associated with a high Gleason Score, advanced clinical stage and metastasis in patients with prostate cancer (32). Enforced miR-335 expression decreased the growth and metastatic characteristics of prostate cancer cells in vitro (32). Sun et al (33) identified that miR-335 was downregulated in more invasive colorectal cancer tissues and cell lines.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑335 is downregulated in papillary thyroid cancer and suppresses cancer cell growth, migration and invasion by directly targeting ZEB2

Kan

Yang

2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) are a group of short, endogenous, non-protein-coding and single-stranded RNAs that regulate gene expression by binding to the 3'-untranslated region (3'UTR) of mRNAs, which results in their degradation or translational repression. The aim of the present study was to investigate the expression and function of miR-335 in human papillary thyroid cancer (PTC). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to quantify the relative miR-335 expression levels in PTC tissues and cell lines. The effect of miR-335 on the proliferation, migration and invasion of PTC cells was assessed by an MTT assay, and transwell migration and invasion assays, respectively. Dual-luciferase reporter assays were employed to explore whether miR-335 directly targeted the 3'UTR of the potential target gene zinc finger E-box binding homeobox 2 (ZEB2). RT-qPCR and western blotting were adopted to assess the effect of miR-335 on the mRNA and protein expression of ZEB2. RT-qPCR revealed that miR-335 was downregulated in PTC tissues and cell lines. The MTT assay and transwell migration and invasion assays demonstrated that the overexpression of miR-335 significantly inhibited the proliferation, migration and invasion of PTC cells. ZEB2 was identified as a direct target of miR-335 with computational analysis, which was confirmed with a dual-luciferase reporter assay, RT-qPCR and western blotting. The knockdown of ZEB2 significantly inhibited the proliferation, migration and invasion of PTC cells, indicating that ZEB2 may be a functional target of miR-335. Taken together, these findings suggested that miR-335 functioned as a tumor suppressor and suppressed the growth and metastatic behavior of PTC cells by targeting ZEB2. IntroductionThyroid cancer is the most common subtype of endocrine malignancy, with 300,000 new cases per year, and ~40,000 mortalities per year, worldwide (1). The incidence of thyroid cancer has increased in recent decades (2). It can be categorized into four major histologic groups, including papillary thyroid cancer (PTC), follicular thyroid cancer, poorly differentiated carcinoma and anaplastic thyroid cancer (3). PTC accounts for 80-90% of all thyroid cancer cases (4).A number of factors have been demonstrated to be associated with PTC progression, including genetic factors, environmental exposure, epigenetic alteration, nodular disease of the thyroid and radiation exposure (5,6). The prognosis of PTC patients is associated with their age, tumor size, lymph node invasion and distant metastasis (7). Currently, the standard therapeutic treatment for PTC is complete thyroidectomy followed by radioiodine and levothyroxine therapy (8). However, ~10% of patients with PTC develop recurrence and metastasis, which are associated with poor prognosis (9). Thus, it is necessary to characterize the molecular mechanisms of PTC initiation and development, and to develop novel, targeted therapies for PTC.The abnormal expression of microRNAs (miRNAs/miRs) has been implicated in ...

show abstract

“…miR-335 underexpression has been validated in three studies [19,29,32] and this microRNA is considered to be a potent tumor suppressor microRNA in several human cancer tissues [42,43]. No data are available yet on its targets in the adrenal cortex, but in other tissues miR-335 suppresses tumor cell migration, invasion, and metastasis [44][45][46][47] (Table 2).…”

Section: Micrornas In Adrenocortical Cancermentioning

confidence: 99%

MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy

Igaz

Nagy

et al. 2014

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Several lines of evidence support the relevance of microRNAs in both adrenocortical and adrenomedullary (pheochromocytomas) tumors. Significantly differentially expressed microRNAs have been described among benign and malignant adrenocortical tumors and different forms of pheochromocytomas that might affect different pathogenic pathways. MicroRNAs can be exploited as markers of malignancy or disease recurrence. Besides tissue microRNAs, novel data show that microRNAs are released in body fluids, and blood-borne microRNAs can be envisaged as minimally invasive markers of malignancy or prognosis. MicroRNAs might even serve as treatment targets that could expand the rather-limited therapeutic repertoire in the field of adrenal tumors. In this review, we present a critical synopsis of the recent observations made in the field of adrenal tumor-associated microRNAs regarding their pathogenic, diagnostic, and potential therapeutic relevance.

show abstract

MicroRNA-335 Acts as a Candidate Tumor Suppressor in Prostate Cancer

Cited by 36 publications

References 23 publications

PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells

PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells

MicroRNA‑335 is downregulated in papillary thyroid cancer and suppresses cancer cell growth, migration and invasion by directly targeting ZEB2

MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy

Contact Info

Product

Resources

About